Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 9—September 2018

Zika Virus Seropositivity in 1–4-Year-Old Children, Indonesia, 2014

R. Tedjo SasmonoComments to Author , Rama Dhenni, Benediktus Yohan, Paul Pronyk, Sri Rezeki Hadinegoro, Elizabeth Jane Soepardi, Chairin Nisa Ma’roef, Hindra I. Satari, Heather Menzies, William A. Hawley, Ann M. Powers, Ronald Rosenberg, Khin Saw Aye Myint, and Amin Soebandrio
Author affiliations: Eijkman Institute for Molecular Biology, Jakarta, Indonesia (R.T. Sasmono, R. Dhenni, B. Yohan, C.N. Ma’roef, K.S.A. Myint, A. Soebandrio); UNICEF Indonesia, Jakarta (P. Pronyk); University of Witwatersrand School of Public Health, Johannesburg, South Africa (P. Pronyk); Universitas Indonesia Medical School, Jakarta (S.R. Hadinegoro, H.I. Satari); Cipto Mangunkusumo Hospital, Jakarta (S.R. Hadinegoro, H.I. Satari); Ministry of Health of the Republic of Indonesia, Jakarta (E.J. Soepardi); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (H. Menzies, W.A. Hawley); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (A.M. Powers, R. Rosenberg)

Cite This Article


We assessed Zika virus seroprevalence among healthy 1–4-year-old children using a serum sample collection assembled in 2014 representing 30 urban sites across Indonesia. Of 662 samples, 9.1% were Zika virus seropositive, suggesting widespread recent Zika virus transmission and immunity. Larger studies are needed to better determine endemicity in Indonesia.

Zika virus, first isolated in 1947 (1), is a flavivirus phylogenetically related to dengue virus (DENV) that is, like DENV, also transmitted by Aedes mosquitoes. Because of the epidemic that swept through the Americas in 2016, Zika virus infection is known to cause microcephaly, as well as other congenital defects and Guillain-Barré syndrome (2).

Zika virus has long been known to be endemic in Southeast Asia (3,4), but laboratory confirmation of infection can be challenging. Acute infections are often asymptomatic. In those who are symptomatic, viral RNA typically persists in blood <7 days and in urine <10 days after symptom onset, limiting the usefulness of nucleic acid testing (5). Zika virus antibody cross-reacting with DENV can confuse results of tests conducted in regions where the viruses co-circulate (6). Virus-specific neutralization assays can more accurately detect and measure Zika virus antibody, but because of their complex requirements, these tests have seldom been used in epidemiologic studies (7).

Acute Zika virus cases have been reported in Indonesia (8), Singapore (9), Malaysia (10), Vietnam (11), and Thailand (12). However, little is known about Zika virus prevalence in the region. Limited retrospective testing of archived specimens collected from clinically ill patients in Thailand (12) and Cambodia (13) suggest that incidence in these countries is low. However, given the limited number of samples tested and lack of confirmatory testing in these studies, information on prevalence and distribution is challenging to assess. Likewise, little is known about the prevalence and geographic distribution of Zika virus in Indonesia, the biggest country in Southeast Asia.

DENV and chikungunya virus, also transmitted by Aedes mosquitoes, are endemic throughout Indonesia, suggesting the ecologic conditions exist for Zika virus transmission as well. An estimated 80% of the population in Indonesia is infected with >1 DENV by the age of 10 years (14). In our study, we assessed Zika virus seroprevalence among healthy 1–4-year-old children to determine the prevalence and distribution of Zika virus in Indonesia.

The Study

We used serum samples collected during October–November 2014 for a previous population-based, cross-sectional cluster survey conducted to assess DENV seroprevalence; in the study, 3,312 samples were collected from 1–18-year-old children in 30 urban districts in 14 provinces of Indonesia (14). In our study, we assessed only the children 1–4 years (range 12–59 months) of age because these children were least likely to have cross-reactive DENV antibodies. Ethics clearance was obtained from the Health Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia, and the US Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, USA).

Plaque reduction neutralization tests (PRNTs) that could differentiate Zika virus neutralizing antibodies from those produced in response to DENV infection were adapted from protocols developed by the CDC (Technical Appendix). The challenge virus used in the PRNT was Zika virus JMB-185, acquired from a patient in 2014 (8). Convalescent serum from this same patient was used as a PRNT positive control. We subjected all specimens to 2 tiers of testing by PRNT90 (i.e., a PRNT in which serum samples suppressing >90% of challenge virus were considered positive for neutralizing antibody). In the first tier, we tested serum samples diluted 1:10. Samples that suppressed >90% of Zika virus PFUs were considered potentially positive for Zika virus antibodies because DENV-specific antibodies, if present, could have cross-reacted and neutralized Zika virus. We then subjected the specimens considered potentially positive to a second PRNT90, in which we tested serum samples against Zika virus and all 4 DENV serotypes (Technical Appendix). Specimens that tested positive for Zika virus neutralizing antibody and negative for DENV neutralizing antibody by PRNT90 were classified as Zika virus seropositive, as were specimens that had Zika virus PRNT90 titers >4-fold higher than all DENV PRNT90 titers. We categorized specimens as flavivirus seropositive when Zika virus neutralizing antibodies were present but at titers <4-fold higher than any DENV neutralizing antibody titer (Technical Appendix Table). We also tested a subset of samples for Japanese encephalitis virus antibody by PRNT90; none of the samples tested had a titer >20, and none of the sample classifications were changed after testing.


Thumbnail of Geographic distribution of Zika virus–seropositive 1−4-year-old children, Indonesia, October–November, 2014. The values listed for each province indicate the percentage of serum samples confirmed Zika virus seropositive (percentage serum samples suspected to be Zika virus seropositive). Samples suspected to be Zika virus positive were those that were positive on initial Zika virus PRNT90 (plaque reduction neutralization test with neutralization defined as &gt;90% reduction in challe

Figure. Geographic distribution of Zika virus–seropositive 1−4-year-old children, Indonesia, October–November, 2014. The values listed for each province indicate the percentage of serum samples confirmed Zika virus seropositive (percentage serum samples suspected to...

In the initial PRNT90 screening, we detected possible Zika virus antibody in 73 (11.0%) of the 662 serum samples (Table). Of these, 72 had a sufficient volume to undergo second-tier testing; 60 (83.3%) of 72 samples were Zika virus seropositive, and 12 (16.7%) were flavivirus seropositive. Serum samples from 11 of 14 provinces were Zika virus seropositive, and the collections from the provinces ranged from ≈4.5% seropositive (North Sumatra, Banten, East Kalimantan) to >18% seropositive (Central Java, Jambi; Figure). Overall, Zika virus seroprevalence in the 1–4-year-old cohort was 9.1% (95% CI 3.95%–11.01%).

Our assessment, involving use of the PRNT90, which is highly specific for Zika virus antibodies, indicates widespread, recent Zika virus infection in much of western and central Indonesia. Our criterion for confirmed Zika virus antibodies (i.e., PRNT90 titer for Zika virus >4-fold higher than that for any DENV in the same specimen) is the international standard. In just 2% (12/662) of specimens, we could not determine whether the antibodies were Zika virus or DENV specific. When using the more conservative criterion of only classifying a sample as positive for Zika virus antibodies if no DENV-specific neutralizing antibodies are detected, the number of Zika virus antibody–positive samples decreases by only 6, leaving 54 samples still classified as Zika virus seropositive. Further evidence for the validity of the PRNT90 was that DENV neutralizing antibody–positive samples were negative for the presence of Zika virus neutralizing antibodies across a range of titers (R.T. Sasmono, unpub. data).

Although our data provide some evidence regarding geographic distribution, no information is presented regarding a specific threshold titer associated with clinical illness or a correlation between geography and titer. Further studies involving larger sample sets would be necessary to address these topics. The single age group, relatively small number of specimens, and limited number of sites, particularly from eastern parts of the country, do not give a comprehensive picture of endemicity throughout Indonesia. The small numbers of specimens available from most localities did not enable accurate estimation of the proportional differences between localities. We could perform PRNT90 with samples from the remaining cohort (the 5–18-year-olds), but we expect higher percentages of nonspecific flavivirus seropositivity in the samples from this older age group.


Much has been published on epidemic Zika virus, but little is known about the effect of Zika virus in endemic areas. Determining the prevalence of Zika virus in Indonesia can provide clues to its potential long-term public health significance in endemic settings. Mild or asymptomatic infection is common, and confusion with dengue during diagnosis probably accounts for how long Zika virus was unrecognized in Indonesia and other areas of Southeast Asia. Besides the need to better evaluate Zika virus incidence and distribution, a high priority for future investigations will be determining the extent of Zika virus–related birth defects. If, like other flaviviruses, a primary Zika virus infection results in lifelong immunity, infections during childhood could reduce a person’s risk for infection later in life and thus the incidence of Zika virus–related birth defects. This knowledge provides clues for understanding future patterns of Zika virus transmission in the Americas.

Dr. Sasmono is a senior research fellow at the Eijkman Institute for Molecular Biology, Jakarta, Indonesia. His primary research interests are dengue and other arboviral diseases.



We thank Alain Bouckenooghe and the DNG26 team for specimen collection. Help from Jeremy P. Ledermann and Araniy Fadhilah regarding PRNTs was greatly appreciated.

This work was supported by the Ministry of Research, Technology, and Higher Education of the Republic of Indonesia and CDC, Atlanta, Georgia, USA. Funding for this work was also provided by the Office of Infectious Diseases, Bureau for Global Health, US Agency for International Development, under the terms of an interagency agreement with CDC.



  1. Dick  GWA, Kitchen  SF, Haddow  AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46:50920. DOIPubMedGoogle Scholar
  2. World Health Organization. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. 2016 Feb 1 [cited 2018 Apr 4].
  3. Musso  D, Gubler  DJ. Zika Virus. Clin Microbiol Rev. 2016;29:487524. DOIPubMedGoogle Scholar
  4. Duong  V, Dussart  P, Buchy  P. Zika virus in Asia. Int J Infect Dis. 2017;54:1218. DOIPubMedGoogle Scholar
  5. Paz-Bailey  G, Rosenberg  ES, Doyle  K, Munoz-Jordan  J, Santiago  GA, Klein  L, et al. Persistence of Zika virus in body fluids-preliminary report. N Engl J Med. 2017;NEJMoa1613108. DOIPubMedGoogle Scholar
  6. Lanciotti  RS, Kosoy  OL, Laven  JJ, Velez  JO, Lambert  AJ, Johnson  AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:12329. DOIPubMedGoogle Scholar
  7. Posen  HJ, Keystone  JS, Gubbay  JB, Morris  SK. Epidemiology of Zika virus, 1947-2007. BMJ Glob Health. 2016;1:e000087. DOIPubMedGoogle Scholar
  8. Perkasa  A, Yudhaputri  F, Haryanto  S, Hayati  RF, Ma’roef  CN, Antonjaya  U, et al. Isolation of Zika virus from febrile patient, Indonesia. Emerg Infect Dis. 2016;22:9245. DOIPubMedGoogle Scholar
  9. Ho  ZJM, Hapuarachchi  HC, Barkham  T, Chow  A, Ng  LC, Lee  JMV, et al.; Singapore Zika Study Group. Outbreak of Zika virus infection in Singapore: an epidemiological, entomological, virological, and clinical analysis. Lancet Infect Dis. 2017;17:81321. DOIPubMedGoogle Scholar
  10. Salehuddin  AR, Haslan  H, Mamikutty  N, Zaidun  NH, Azmi  MF, Senin  MM, et al. Zika virus infection and its emerging trends in Southeast Asia. Asian Pac J Trop Med. 2017;10:2119. DOIPubMedGoogle Scholar
  11. Chu  DT, Ngoc  VTN, Tao  Y. Zika virus infection in Vietnam: current epidemic, strain origin, spreading risk, and perspective. Eur J Clin Microbiol Infect Dis. 2017;36:20412. DOIPubMedGoogle Scholar
  12. Buathong  R, Hermann  L, Thaisomboonsuk  B, Rutvisuttinunt  W, Klungthong  C, Chinnawirotpisan  P, et al. Detection of Zika virus infection in Thailand, 2012–2014. Am J Trop Med Hyg. 2015;93:3803. DOIPubMedGoogle Scholar
  13. Duong  V, Ong  S, Leang  R, Huy  R, Ly  S, Mounier  U, et al. Low circulation of Zika virus, Cambodia, 2007–2016. Emerg Infect Dis. 2017;23:2969. DOIPubMedGoogle Scholar
  14. Prayitno  A, Taurel  A-F, Nealon  J, Satari  HI, Karyanti  MR, Sekartini  R, et al. Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children. PLoS Negl Trop Dis. 2017;11:e0005621. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2409.180582

Table of Contents – Volume 24, Number 9—September 2018

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

R. Tedjo Sasmono, Eijkman Institute for Molecular Biology, Jl Diponegoro 69, Jakarta 10430, Indonesia

Send To

10000 character(s) remaining.


Page created: August 15, 2018
Page updated: August 15, 2018
Page reviewed: August 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.